Mitsubishi gets rights to Vertex's VX-950 for hepatitis C
Mitsubishi Pharma has licensed exclusive development and marketing rights in Japan and Far Eastern countries to Vertex Pharmaceuticals' VX-950, an oral protease inhibitor in Phase I for the hepatitis C virus (HCV).
- Includes Contract
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com